Bronchodilator Drugs - Czechia | Statista Market Forecast

The revenue in the Bronchodilator Drugs market in Czechia is estimated to reach US$58.24m in 2024.
It is expected to experience a compound annual growth rate (CAGR 2024-2029) of 3.72%, leading to a market volume of US$69.92m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$17.34bn in 2024.
In Czechia, the market for bronchodilator drugs is experiencing a surge in demand due to the high prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are a vital component in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The Bronchodilator Drugs market in Czechia has been steadily growing over the years, owing to the rising prevalence of respiratory diseases in the region.

Customer preferences: Patients suffering from respiratory diseases in Czechia prefer bronchodilator drugs that offer quick relief from symptoms such as shortness of breath, wheezing, and coughing. They also prefer drugs that have minimal side effects and are affordable.

Trends in the market: One of the significant trends in the Bronchodilator Drugs market in Czechia is the increasing demand for combination therapies. Combination therapies involve using two or more bronchodilator drugs to achieve better treatment outcomes. This trend is driven by the need to provide more effective treatment options to patients with severe respiratory diseases.Another trend in the market is the rising adoption of long-acting bronchodilator drugs. Long-acting bronchodilators provide sustained relief from symptoms and reduce the frequency of exacerbations. This trend is driven by the need to improve patient compliance and reduce healthcare costs associated with hospitalizations.

Local special circumstances: Czechia has a high prevalence of respiratory diseases, with asthma and COPD being the most common. This high prevalence is attributed to factors such as air pollution, smoking, and occupational exposure to respiratory irritants. The high prevalence of respiratory diseases in the region is driving the demand for bronchodilator drugs.

Underlying macroeconomic factors: The Bronchodilator Drugs market in Czechia is also influenced by macroeconomic factors such as healthcare spending and government policies. The Czech government has implemented policies aimed at improving access to healthcare services, including respiratory disease management. This has led to increased demand for bronchodilator drugs in the region. Additionally, the increasing healthcare spending in the region is driving the growth of the market. In conclusion, the Bronchodilator Drugs market in Czechia is growing due to the high prevalence of respiratory diseases in the region. Patients prefer drugs that offer quick relief from symptoms, minimal side effects, and are affordable. The increasing demand for combination therapies and long-acting bronchodilators is a significant trend in the market. The market is also influenced by macroeconomic factors such as healthcare spending and government policies aimed at improving access to healthcare services.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.